Post by John Krlin

When a company’s mission is centered on transforming lives through innovative medical technology, growth becomes more than a financial metric—it becomes evidence of impact. Under the leadership of CEO Mike Mahoney, with Joe Fitzgerald leading Cardiovascular and Art Butcher leading MedSurg, Boston Scientific’s Q1 2026 results tell that story clearly: Cardiovascular → 67.3% of revenue ↘ Interventional Cardiology & Vascular Therapies → 23.9% ↘ Electrophysiology → 17.4% ↘ Cardiac Rhythm Management → 11.1% ↘ WATCHMAN → 9.7% ↘ Interventional Oncology & Embolization → 5.2% MedSurg → 32.7% of revenue ↘ Endoscopy → 14.1% ↘ Urology → 12.4% ↘ Neuromodulation → 6.1% These aren’t just strong numbers. They reflect growing adoption of therapies that help physicians treat complex cardiovascular, neurological, and oncological conditions more effectively. The connection between mission and performance is often discussed in theory. Boston Scientific demonstrates it in practice: invest in innovation, solve meaningful clinical challenges, and create measurable value for patients, providers, and shareholders alike. Growth follows impact. #HealthcareInnovation #MedTech #BostonScientific #Leadership #Healthcare